

Mpox Updates

Healthcare Provider Webinar

Rachel Hart-Malloy, PhD, MPH Director, Office of Sexual Health and Epidemiology New York State Department of Health AIDS Institute

Charles J. Gonzalez, MD Medical Director New York State Department of Health AIDS Institute

Tuesday, May 9, 2023

Eugene P. Heslin, MD, FAAFP First Deputy Commissioner and Chief Medical Officer New York State Department of Health

Moderated by: Kraig Pannell Director, Office of LGBTQ Services New York State Department of Health AIDS Institute

Agenda

Updates on mpox epidemiology – Dr. Rachel Malloy

Review of clinical care & treatment – Dr. Eugene Heslin

NYS preparedness plan – Dr. Charles Gonzalez

Questions/Answers


Please send any questions to **mpox@health.ny.gov**



Mpox Epidemiology Updates Dr. Rachel Malloy




New York City mpox cases over time for 2022





Source: New York City Department of Health and Mental Hygiene; data as of 1/15/23 for 5/19/22-12/31/22 only


New York State* mpox cases over time



Confirmed/probable mpox cases, *NYS (excluding NYC) residents and cumulative cases counts by day of diagnosis Source: New York State Department of Health; data as of 5/3/23



New York State* mpox cases by region




Confirmed/probable mpox cases by NYS region and county (*excl. NYC) Source: New York State Department of Health; data as of 5/3/23



National mpox cases over time

Daily Mpox Cases & 7 Day Daily Average, USA





Data as reported to CDC as of April 26, 2023, 2pm **Source:** Centers for Disease Control and Prevention (CDC)

Global cumulative cases and deaths, recent cases

WHO Region	Total Confirmed Cases	Total Deaths	Cases in last 3 weeks ⁱ	3-week change in cases (%)
Region of the Americas	59 220	104	155	-43%
European Region	25 881	6	27	350%
African Region	1477	18	0 ⁱⁱ	_ ⁱⁱⁱ
Western Pacific Region	406	0	62	35%
Eastern Mediterranean Region	85	1	2	100%
South-East Asia Region	44	1	1	-67%
Total	87 113	130	247	-30%

Cumulative confirmed mpox cases and deaths reported to WHO by WHO region; 1/1/22 – 4/24/23 Source: World Health Organization




ⁱ Using the three most recently completed international standard weeks (Monday - Sunday)

ⁱⁱ The African Region has not reported any new cases in the last 21 days; however, this is due to disruptions to reporting and should be interpreted accordingly.

iii (-) Zero cases were reported in at least one of the three-week periods in the past six weeks

CDC risk assessment of mpox resurgence





Probability and predicted size of mpox outbreaks by population immunity levels Source: Centers for Disease Control and Prevention (CDC)


Co-infection rates with HIV and STIs are high

In NYS and nationally, we see high rates of co-infection with mpox among persons living with HIV, as well as among persons diagnosed with an STI in the past year.

Among mpox diagnoses in NYS* as of 9/9/22:







were diagnosed with an STI in the 12 m. prior to mpox diagnoses

Immunocompromised e.g. PLWH at risk for severe mpox

Data from patients hospitalized with severe mpox between August 10 to October 10, 2022, found that of 57 adult patients for which CDC provided clinical consultations:

- 47 (82%) were living with HIV
 - Only 4 (9%) were receiving ART before their mpox diagnosis
 - 68% of patients were non-Hispanic Black

A subsequent report on mpox-associated fatalities found that among 33 decedents with available information between 5/10/22 and 3/7/23:

93.9% were immunocompromised due to HIV

CDC recommends testing all sexually-active patients with suspected mpox for HIV as well, unless patient is already known to have HIV+-

Source: Miller MJ, Cash-Goldwasser S, Marx GE, et al. Severe Monkeypox in Hospitalized Patients — United States, August 10– October 10, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1412–1417. DOI: <u>http://dx.doi.org/10.15585/mmwr.mm7144e1</u>; Riser AP, Hanley A, Cima M, et al. Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023. MMWR Morb Mortal Wkly Rep 2023;72:404–410. DOI: <u>http://dx.doi.org/10.15585/mmwr.mm7215a5</u>

NEW YORK

Department

of Health

Clinical Care & Treatment Dr. Eugene Heslin



Mpox symptoms

Symptoms of mpox can include:

- Rashes, bumps, or blisters on or around the genitals or in other areas like your hands, feet, chest, or face
 - Locations likely reflect points of contact
 - Frequent initial complaint proctitis
 - Many cases identified at sexual health clinics, look similar to other STIs
- Flu-like symptoms, such as fever, headache, muscle aches, chills, and fatigue; these symptoms may occur before or after the rash appears, or not at all

Photo Credits: NHS England High Consequence Infectious Diseases Network, UK Health Security Agency; via Centers for Disease Control and Prevention (CDC)





Mpox testing for providers

For providers:

Many commercial and clinical laboratories can provide testing:

- <u>NYS orthopox testing laboratories</u>
- FDA mpox testing laboratories

Especially among persons with epidemiologic risk factors for mpox infection, submission of specimens should occur

Guidance from the CDC on specimen collection and transport can be found <u>here</u>

For the public:

If persons are exhibiting symptoms of mpox, they are encouraged to healthcare provider right away

If you do not have a healthcare provider, please see the <u>AI provider directory</u> to locate one

NYC residents can visit the <u>NYC Health</u> <u>Department mpox page</u> for what to do when experiencing symptoms



Mpox clinical updates

NYS released updated health advisory for healthcare providers 5/1:

- Updated outbreak status and mpox terminology
- Clarifies addition of mpox to NYCRR list of STIs
- Updates to NYS vaccine strategy
- Reporting requirements

NEW YOF STATE OF OPPORTUNIT	Department	
KATHY HOCHUL	JAMES V. McDONALD, M.D., M.P.H.	MEGAN E. BALDWIN
Governor	Acting Commissioner	Acting Executive Deputy Commissioner
		May 1, 2023
Provis Colleg Medic	hcare Providers, Hospitals, Local Health Departm ders, Family Planning Providers, Emergency Roo ge Health Centers, Community-Based Organizatio ine, Pediatric, Adolescent Medicine, Dermatology Providers	ms, Community Health Centers, ons, and Internal Medicine, Family
Comr	York State Department of Health (NYSDOH) AID nunicable Disease Control (BCDC), Immunization ions (BHAI)	
HEALT	TH ADVISORY: MPOX CASES ASSOCIATED W TRANSMISSION	ITH PERSON-TO-PERSON
SUMMARY:		
world	May 14, 2022, >86,000 cases of mpox have bee wide where mpox virus is not endemic, including :	
	s. suggest that individuals who identify as gay, bises nen comprise the majority of reported cases in the	
 Regarder percertain 	rdless of gender identity, birth sex, sex of sex part ived risk factors, providers should be alert for pati	tner(s), travel, and/or specific or
 Clinic 	stent with mpox. lans suspecting mpox infection should strictly adh re required to immediately notify their local health	
 This a 	re required to immediately nousy their local health advisory provides updates to <u>NYSDOH Health Ale</u> State - July 8, 2022 .	
	pdates include: Background on status of mpox outbreak, includi	ing the updated name "mpox"
	from "monkeypox" Addition of mpox to the list of sexually transmitte Codes, Rules, and Regulations (NYCRR) Title	
	NYS Vaccine Strategy (outside of NYC) Testing	
	Obtaining tecovirimat (TPOXX) for treatment or Reporting requirements	postexposure prophylaxis
Background	and Clinical Presentation of Mpox	
Mpox (previo	usly known as monkeypox) is an infectious disea irus. In November 2022, the World Health Organi	
monkeypox v		



JYNNEOS vaccination updates



No longer restrictive eligibility – eligibility in NYS includes all who are at risk, in accordance with <u>CDC</u>

 Inclusive of those who self-identify as being at risk – specific identities or risk behaviors need not be disclosed

Route of administration

- Subcutaneous recommended
- Alternative (intradermal) admin accepted



Reporting

- Healthcare providers must immediately report suspect cases of mpox to their local health department (LHD). No change in process.
- If you are unable to reach the LHD where the patient resides, please contact the **NYSDOH Office of Sexual Health and Epidemiology** (518-474-3589) during business hours (After hours, weekends, holidays: 866-881-2809)



Obtaining Tecovirimat

NYC providers – instructions for prescribing tecovirimat for eligible patients can be found here [NYC 2022 Health Advisory 16: Accessing Tecovirimat for People with Mpox]

NYS (Rest of State-ROS) providers – instructions for accessing tecovirimat can be found on the CDC's webpage and 5/1 NYSDOH health advisory

ROS providers can consult the <u>NYS mpox provider</u> treatment network



2022 Health Advisory #16: Accessing Tecovirimat for People with Monkeypox

- Many people with monkeypox in New York City (NYC) have developed complications including proctitis, which can progress to become severe and debilitating, and lesions in anatomical sites at risk of scarring or other permanent sequelae. Supportive care, including pain control, is a mainstay of treatment.
- Tecovirimat (TPOXX) is an antiviral medication available through the Centers for Disease Control and Prevention (CDC) that is being used to treat monikeypox infection under CDC's Frananded Access Investigational New Drug (IND) protocol. To date, tecovirimat has been prescribed for over 400 patients in NYC.
- Recently the FDA and CDC simplified this protocol so that treatment with tecovirimat can begin upon obtaining informed consent from the patient. No pre-registration is required and evaluations can be done by telemedicine. Additional forms must be submitted to CDC after inflating treatment.
- Providers are urged to take the necessary steps to prescribe tecovirimat when indicated for the patients that have a opisitive test result (or are awailing test results and have a clinically compatible illness). NYC providers who want to prescribe tecovirimat and can adhere to the IND protocol can email <u>Ar/NtherapeuticalPhasth.nyc.app</u> (in information on free delivery to patients or to request supplies for a pharmapy at their facility.
- For more information about monkeypox, visit the NYC Department of Health and Mental Hygiene's <u>Monkeypox Information for Providers</u> webpage.

August 2, 2022

Dear Colleagues,

The number of people diagnosed with monkeypox continues to rise in <u>New York City (NYC)</u>, the <u>US</u> and <u>Other continuing</u>. On July 23, 2021; the Work Mealth Organisation declared MWA Eublidy <u>Health Emergency of International Contern</u>; on July 28, the New York State Department of Health declared monkeypox an <u>Imminiant Threat to Public Health</u> and, on July 28, the State declared a <u>State Onserver</u>; and On July 30, the NYC Department of Health and Mental Hygiene (Health Department) declared monkeypox a <u>Fublic Health Emergency</u>, and on August 1, the City declared <u>State of mergency</u>.

This Health Advisory provides information on the antiviral tecovirimat (TPOXX) including indications for use and how prescribe it to your patients.



NYS Mpox Provider Treatment Network


Institution	Region	To Contact Outside NYC MPV Provider Treatment Network
Albany Medical Center	Capital	518-264-4769 (518-264-4POX)
SUNY Upstate	Central	315-464-3979
University of Rochester	Finger Lakes	https://www.urmc.rochester.edu
Northwell	Long Island	1-833-315-1748
SUNY Stonybrook	Long Island	(631) 638-7973; https://www.stonybrookmedicine.edu
Mount Sinai South Nassau	Long Island	516-255-8410; <u>https://www.southnassau.org</u>
Montefiore - Nyack (Jacobs Family Pride Wellness Center)	Mid Hudson	(845) 348-7284
Westchester Medical Center	Mid Hudson	914-326-2060; <u>https://www.wmchealth.org</u>
Vassar	Mid Hudson	Fax a referral to 845-471-0267. Please specify in the comments that the referral is "FOR MONKEYPOX TREATMENT"
Mohawk Valley Health System	Mohawk Valley	Khall3@mvhealthsystem.org
Champlain Valley Physicians Hospital	North Country	518-561-2000
Canton-Potsdam Hospital	North Country	ID Clinic Call Center - (315) 268-5810
United Health Services	Southern Tier	607-763-5991
ECMC Hospital	Western	https://www.ecmc.edu
VA Western New York Healthcare System	Western	only for enrolled veterans



NYS Preparedness Plan Dr. Charles Gonzalez




Priority #1: Expand vaccine coverage, increase equity



First and second dose coverage, as a percentage of population at risk for mpox Source: Centers for Disease Control and Prevention Fully vaccinated (2 doses)




Priority #1: Expand vaccine coverage, increase equity



Cases and first dose vaccinations by race/ethnicity | Those with a race/ethnicity categories as "unknown" were not included in these data – 55 (14.7%) cases and 1,073 (6.4%) first dose vaccinations to date | **Source:** New York State Department of Health

Vaccine is available across New York State



Note: Not all vaccination sites are listed here; list subject to change. **Source:** CDC mpox vaccine locator

NEW YORK

STATE

Department

of Health

Mpox categorized as an STI in NYS

Why:

- Patient counseling
- Isolation requirements
- Minors
- Disease Information Services/DIS Partner Services

Monkeypox Virus to the List of Sexually Transmitted Diseases (STDs) Effective: 10/6/22 – 1/3/23

Pursuant to the authority vested in the Public Health and Health Planning Council and the Commissioner of Health by sections 225(4), 2304, 2305 and 2311 of the Public Health Law, Section 23.1 of Title 10 of the Official Compilation of Codes, Rules and Regulations of the State of New York is amended, to be effective upon filing with the Secretary of State, to read as follows:

Group B of Section 23.1 is amended to read as follows: Group B

Facilities referred to in section 23.2 of this Part must provide diagnosis and treatment, including prevention services, as provided in section 23.2(d) of this Part for the following STDs:

Human Papilloma Virus (HPV)

Genital Herpes Simplex

Human Immunodeficiency Virus (HIV)

Monkeypox Virus (MPV)



Behavioral Change to Prevent Mpox



The warmer months are full of events that celebrate the LGBTQ+ community. Preparing for this season is a great opportunity to make sure that you stay healthy before, during, and after these celebrations.

Safer Sex, Social Gatherings, and Mpox

While CDC works to contain the current mpox outbreak and learn more about the virus, this information can help you make informed choices when you are in situations or places where mpox could be spread. Mpox is often transmitted through close, sustained physical contact, almost exclusively associated with sexual contact in the current outbreak.

How can a person lower their risk during sex?

Vaccination is an important tool in preventing the spread of mpox (formerly known as monkeypox). If you are at risk for mpox but haven't received your two-dose vaccine yet, temporarily changing some parts of your sex life might reduce the risk of exposure to the virus. This includes the time between your first and second shots of vaccine. Your protection will be highest two weeks after your second dose of vaccine.

Make a habit of exchanging contact information with any new partner to allow for sexual health follow-up, if needed.

Talk with your partner about any mpox symptoms and be aware of any new or unexplained rash or lesion on either of your bodies, including the mouth, genitals (penis, testicles, vulva, or vagina), or anus (butthole). If you or your partner has or

recently had mpox symptoms, or you have a new or unexplained rash anywhere on your body, do not have sex and see a healthcare provider. In some cases, symptoms may be mild, and some people may not even know they have mpox.





Source: Centers for Disease Control and Prevention: <u>https://www.cdc.gov/lgbthealth/summer/index.html</u>; https://www.cdc.gov/poxvirus/mpox/prevention/sexual-health.html

Behavioral Change to Prevent Mpox

Morbidity and Mortality Weekly Report

Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with Men to Prevent *Monkeypox virus* Transmission — United States, August 2022

Kevin P. Delaney, PhD¹; Travis Sanchez, DVM²; Marisa Hannah, MPH²; O. Winsdow Edwards, MPH²; Thomas Carpino, MPH³; Christine Agnew-Brune, PhD¹; Kayfin Renfo, PhD¹; Rachd Kachur, MPH¹; Neal Carnes, PhD¹; Eltzheith A. DiNenno, PhD¹; Amy Lansky, PhD¹; Kathlene Entier, PhD¹; Parick Sallivan, PhD²; Stefan Baral, MD³; Alexan A. Oster, MD³

On August 26, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). The first U.S. case of monkeypox during the current outbreak was confirmed on May 17, 2022 (1); on August 4, the U.S. Department of Health and Human Services declared the outbreak to be a public health emergency.* To date, most reported monkeypox cases in the United States and globally have occurred among men who reported sexual or close intimate contact with another man during the 3 weeks before symptom onset (2). The multipronged response to monkeypox has included expanding access to monkeypox vaccine and developing messaging[†] for gay, bisexual, and other men who have sex with men (MSM) seeking to reduce their chances for acquiring monkeypox. During August 5-15, 2022, a monkeypox-specific follow-up survey was completed by a convenience sample of 824 MSM who responded to the annual American Men's Internet Survey (AMIS).§ Overall, 48% of respondents reported reducing their number of sex partners, 50% reported reducing one-time sexual encounters, and 50% reported reducing sex with partners met on dating apps or at sex venues since learning about the monkeypox outbreak. Nearly one in five respondents reported receiving ≥1 dose of vaccine to prevent monkeypox. Receipt of vaccine was preceding the survey (3). During August 5–15, 2022, AMIS 2021 survey participants who agreed to be recontacted were invited to complete a follow-up survey assessing knowledge of and experiences with monkeypox. After providing research consent, participants answered questions about general knowledge, awareness, and concern about monkeypox; personal behavior changes during the past 3 months because of the monkeypox outbreak; and receipt of vaccine to prevent monkeypox infection. The Emory University Institutional Review Board reviewed and approved procedures for the AMIS survey. This activity was also reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.

Overall, 2,999 AMIS 2021 participants were invited to participate in the monkeypos survey, and 824 (27,5%) responded and completed all questionnaire sections. Among these respondents, 70.5% were White, and 50.9% were aged <45 years. Most men (90.0%) reported sex with a man during the preceding 3 mouths (i.e., during the current monkeypox outhreak), 238 (28.9%) reported woo runes sex partners during the preceding 14 days. Respondents were from all regions of the United States; (47.8%) lived in urban areas.

Respondents reported changing sexual behaviors since they

~50%

- Decreased their number of partners
- Decreased one-time sexual encounters
- Decreased sex with partners met on apps or at sex venues
- Decreased group sex

42%

Decreased going to sex venues/events

35%

 Decreased going to social events with close contact (dance parties / raves)

Source: Delaney KP, Sanchez T, Hannah M, et al. Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with Men to Prevent Monkeypox virus Transmission — United States, August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1126-1130. DOI: http://dx.doi.org/10.15585/mmwr.mm7135e1



Absent contraindication, vaccination is recommended for:

Vaccine eligibility in line with CDC guidance:

•Those with known or suspected exposure to someone with mpox

•Those with a sex partner in the previous two weeks who was diagnosed with mpox

•Those who identify as gay, bisexual, or other men who have sex with men, as well as transgender, nonbinary, or gender-diverse person who in the past 6 months has had any of the following:

•A new diagnosis of one or more STIs (e.g., chlamydia, gonorrhea, or syphilis)

•More than one sex partner

•Those who have had any of the following in the past six months:

•Sex at a commercial sex venue (e.g., sex club or bathhouse) or private sex party.

•Sex related to a large commercial event or in a geographic area (e.g., city or country) where mpox transmission is occurring

•Those who engage in transactional sex

•Those with a sex partner with any of the above risks

•Those who anticipate experiencing any of the above scenarios

•Persons living with HIV (PLWH) or other causes of immune suppression who had recent or anticipate future risk of mpox exposure from any of the above scenarios

•Those who work in settings where they may be exposed to mpox:

•Those who work with orthopoxviruses in a laboratory

•Those who are part of an orthopoxvirus health care worker response team

The above criteria should also include those who self-identify as being at risk or acknowledge the possibility of or anticipate engaging in risk behaviors in the near future, without needing to disclose specific identities or risk behaviors.



Second doses, and vaccination after mpox

JYNNEOS is a 2 dose vaccine series, with doses administered four weeks (28 days or 4 weeks) apart. Based on ACIP best practices, a second dose may be administered up to four days before the minimum 28-day interval

Providers offering JYNNEOS vaccine should make efforts to schedule second dose appointments for individuals upon receipt of the first dose

Individuals who were previously received one dose of JYNNEOS or had a mpox infection should be encouraged to receive a second or a first dose respectively as soon as feasible



Mpox funded providers

In addition, the AIDS Institute distributed \$2.8M in funding to 14 (12 regional and 2 state-wide) providers to support the delivery of community-based services, build awareness of mpox, and support access to mpox services including testing, treatment, and vaccination Funded providers outside NYC: Southern Tier: STAP, Inc. Central New York: ACR Health Western New York: Evergreen Health Services, Inc. Finger Lakes: Trillium Health **Capital Region and North Country:** Alliance for Positive Health Hudson Valley: Hudson Valley Community Services **Nassau County:** North Shore University Hospital Suffolk County: Long Island Crisis Center



Resources



Vaccine information:

New York City Providers:


- Email: <u>poxvax@health.nyc.gov</u>
- NYC Health Department Provider Access Line: 866-692-3641
- <u>NYC mpox webpage for</u> providers

NYS outside NYC:

- Email: <u>mpox@health.ny.gov</u>
- <u>NYS mpox webpage for</u> providers



NYS Campaign Materials



It takes two.

VORK Department

To hug ... To tango ... Two doses to protect yourself from mpox. Start your mpox vaccine series today!



All available at health.ny.gov/mpox under "resources"



4/23

Additional Resources

- Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak (CDC)
- <u>Safer Sex, Social Gatherings, and Mpox (CDC)</u>
- <u>Get Healthy and Ready for Summer 2023 (CDC)</u>
- List of Laboratories Offering Notified Lab-Developed Mpox Tests (FDA)
- <u>New York State Mpox Main Page</u>
- <u>New York City Mpox Main Page</u>



Thank you!

Questions?

mpox@health.ny.gov

